Back to search results

Lattice Radiotherapy for Large Tumors

This study is looking at a special type of radiation therapy called Lattice Radiation Therapy (LRT) for adults with large tumors. LRT is a focused radiation treatment designed to reach the deepest parts of large tumors. Researchers want to see if LRT, when given before standard palliative radiation therapy (treatment to relieve symptoms), is safe and helps shrink tumors. You might be able to join if you have a confirmed cancer diagnosis, a large tumor (at least 4.5 cm), and are planning to receive palliative radiation. The main goal is to check for serious side effects within 90 days. This study is currently unclear on its recruitment status and plans to enroll 25 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 25 participants.
What's involved
Participants will have one additional radiation treatment (LRT) before starting palliative radiation. Their progress will then be followed for one year.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for one year after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07647679

Lattice Radiotherapy for Adults With Large Tumors

Not Yet Recruiting
NAAges 18+InterventionalTreatment
Duke University
~25 participants
Updated 2026-07-01 on ClinicalTrials.gov
What's tested:Lattice Radiation Therapy (LRT)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Radiotherapy (RT) treatment-related, non-hematologic Common Terminology Criteria for Adverse Events (CTCAE) v6.0 Grade ≥ 3 toxicity and Adverse Events of Special Interest (AESI) at 90 days
Measured over 90 days

Conditions

Large Tumor
Palliative Radiotherapy

Explore related trials

Large Extracranial Tumor

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Trey Mullikin, MD · PRINCIPAL_INVESTIGATOR · Duke Health

Who to contact

Heather Franklin, RN BSN OCN
[email protected]
919-668-3726
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically or cytologically confirmed malignancy diagnosis
Radiographic evidence of large extracranial tumor (≥ 4.5 cm)
Patients with primary or metastatic extracranial tumors may be included
Planned to undergo palliative radiation treatment
Life expectancy of at least 3 months
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3
Patient must sign study-specific informed consent

Exclusion

Primary lesion with radiosensitive histology (i.e. germ cell tumors, lymphoma, leukemia, and multiple myeloma)
Prior radiation treatment that overlaps with any planned site of protocol radiotherapy that would preclude further palliative RT.
Receiving concurrent cytotoxic cancer therapy regimens or Vascular Endothelial Growth Factor (VEGF) inhibitor that would overlap with LRT administration. Cytotoxic chemotherapy, targeted therapies, small molecule inhibitors, or sVEGF inhibitors prior to radiation treatment or planned after radiation delivery are allowed at the discretion of the treating radiation oncologist.

What this trial measures

  • Incidence of Radiotherapy (RT) treatment-related, non-hematologic Common Terminology Criteria for Adverse Events (CTCAE) v6.0 Grade ≥ 3 toxicity and Adverse Events of Special Interest (AESI) at 90 days90 days

    Incidence reported as the number of events divided by the study population.